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Abstract 
Natural products have been a fundamental source of medicinal scaffolds for decades; with sixty 
percent of marketed drugs. Many synthetic chemists are focused on synthesizing potent and 
nontoxic compounds for pharmaceutical targets, however, nature is still proving to be a source of 
new bioactive compounds. Produced by the host organism for defense, reproduction and 
communication, secondary metabolites also demonstrate promising bioactivity against human 
pathogens. Hence, natural product chemists continue their quest for new leads. 
As a continuation of these efforts, this thesis attempts to explore fungi and sponges for new 
chemistry, and ultimately, new drug candidates. Antarctica is largely untapped; hence herein two 
Antarctic sponges were chemically investigated. This resulted in isolation and characterization of 
two metabolites. Concurrently, chemical investigation of fungus, from Floridian mangrove 
species, resulted in the isolation of two structurally diverse metabolites. Further, a dereplication 
process was applied to MPLC fractions, which lead to the identification of known metabolites and 
mycotoxins. This enabled prioritization of fractions for future studies.  
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1. Marine natural Products 
1.1. Natural Products as Sources of Drugs  
Medicine derived natural resources have represented an integral source for the treatment of human 
ailments since ancient times. Natural products have had a dominant role in drug development, with 
60% of today’s currently approved drugs containing either a natural products or natural product 
derivatives.1 The terrestrial and aquatic biodiversity of the world is expansive and remains largely 
untapped. The bestselling hypocholesterolemic drug, atorvastatin, has over $125 billion sales over 
14.5 years and can trace its origin to a fungal metabolite from Penicillium citrium, thus illustrating 
how the pharmacophore of natural products can be successfully incorporated into synthetic 
medicines ultimately yielding an increase in chemical diversity of newly approved drugs.2,3,4 
 
Atorvastatin  
Despite natural products potential as exceptional drug candidates, studies indicate that the majority 
of recently approved drugs are biologics rather than the classical small molecules. This trend is 
illustrated amongst pharmaceutical companies that are now refocusing their interest towards 
investments in the development of biologicals.2 One potential factor for the decreasing interest in 
small molecules is the lack of chemical diversity in drug discovery libraries. These libraries are 
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primarily based on Lipinski’s rule of five of which most natural products or their derivatives are 
excluded.5 In contrast, most natural products, including the approved drugs, have lower 
hydrophobicity, increased polarity, fewer aromatic rings and larger molecular size.2 Natural 
product drug discovery is mostly challenged by the process of purification, characterization, and 
modification of otherwise complex skeletons. 2  Due to difficulties involved in these steps, natural 
product scaffolds only account for 17% of the compounds in drug discovery libraries.2 This low 
total percentage is representative of the underutilization of terrestrial and aquatic biodiversity, 
despite their overwhelming abundance. However, despite the growing interest in biologicals, small 
molecules continue to be the most reliable source for intracellular targets. 
1.2. Development of Drugs from Marine Sources  
Due to humans’ acclimation to terrestrial environments, most early interest in natural product 
studies explored terrestrial environments. Antibiotics such as penicillin, cephalosporin, are some 
of the many drugs developed from terrestrial natural products. However, studies of marine 
organisms became possible with the advent of the self-contained underwater breathing apparatus 
(SCUBA) in the 1950’s, allowing scientists to explore the chemical potential of the marine 
benthos. Marine waters are a reservoir of diverse biota that are forced to compete for survival 
through chemical warfare. This leads to an incredible diversity of marine natural products which 
contain plethora of bioactive properties; many of which have spurred interest in aquatic research. 
Until recently, most marine studies were staged in the tropical areas which have proven to be one 
of the most chemically biodiverse environments on earth.6 However, scientists have recently 
expanded their search to cold water environments. Along with concomitant advancement in 
chromatographic and spectroscopic techniques, this inclusion of organisms from colder waters has 
resulted in greatly enhanced chemodiversity available for biological study.7 
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     Penicillin G                                                                                             Cephalosporin  
With 70% of the earth’s surface covered by water, the oceans contain a wealth of biodiversity. But 
beyond the biological diversity, marine environments also provide interesting chemical diversity. 
This chemical diversity, mostly orchestrated by interactions between predators and preys, is due 
to their need for chemical protection.8,9  This chemically complex environment, produced mostly 
by invertebrates, has led to the discovery of a plethora of compounds for marine natural product 
chemists to elucidate the structure of, understand their importance to the environment, and most 
importantly test their bioactivity against harmful pathogens. 
Whilst many marine organisms are mobile, a sizeable number are also sessile. Protection against 
predators for marine life is exhibited in several ways. The mobile marine organisms can escape 
danger physically; others have hard external shells or spicules, and the remaining rely on chemicals 
to protect themselves. Such organisms, including sponges, corals, and tunicates use highly 
specialized secondary metabolites for protection, communication and reproduction.10 The sources 
of these structurally diverse metabolites could be through their own biosynthetic pathways, 
sequestration from their diet, or from symbiotic endo- and epiphytic microbes.11,12  
The competition for space, nutrients and light has led these organisms to develop different defenses 
to ensure their survival. Without these evolutions, natural selection would have led to a reduction 
in population. In this way, sponges rely heavily on chemical defenses. Secondary metabolites are 
products of primary metabolites which are not directly involved the reproduction, growth, and 
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development of the organism, but rather exist primarily for maintaining homeostasis and 
protection. Normally, these metabolites are isolated from cells, whole organisms, or 
biofluids.13,14,15 
  Secondary metabolites exhibit varying structural and chemical features, but rather exist primarily 
for maintaining homeostasis and protection. Several studies have shown that the compounds which 
are developed for these purposes tend to show bioactivity against a range of diseases.16,17,18 The 
bioassay studies of these organisms proved to be promising for a wide range of diseases or 
agricultural pests.  
In this regard, compounds from marine sources have been screened through a broad spectrum of 
biological assays, such as: fungal, neurodegenerative, viral, immunosuppressive, cancer, 
antibacterial, neurotoxic and cardiovascular. 19 At the end of 2017, seven marine derived drugs 
have been approved by the U.S. Food and Drug Administration (FDA) including compounds 
named omega-3-acid ethyl esters, cytrabine  (ara-C), vidarbine (ara-A), and eribulin mesylate.17   
 
 
Omega-3-acid ethyl esters 
                                  
                              Ara-A                                                                                           Ara-C 
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Additionally, there are marine-derived substances which have shown potent anticancer properties 
and are currently at various stages of clinical trials. Plitidepsin, Prbinectedin, and Glembatumumab 
Vedotin are in Phase III clinical trials while candidates such as ASG-67E, ASG-15ME, ABBV-
221, Marizomib, and ABBV-085 are currently in Phase I trials.17  Furthermore, there are thousands 
of natural molecules isolated each year with bioactivity against different therapeutic targets, 
therefore confirming the potential of natural products as a rich reservoir of compounds with 
promising bioactivity.17, 18,20 
With reference to anticancer drugs approved by the FDA from 1981-2014, 113 of 136 (83%) are 
non-biologics, either from natural products,  based on natural products, or natural product mimics.3 
One recently approved example is ingenol mebutate.3 This compound was approved in 2012 for 
actinic keratosis, a precancerous condition which can lead to melanoma.   
 
 
Ingenol mebutate 
Interestingly, but perhaps not surprisingly, a great deal of chemical diversity is attributed to the 
species of origin from which natural products are isolated.  Different groups of marine organisms 
will contain distinctive compounds based on their needs to enhance survival, and thus it is crucial 
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to investigate a vast array of sponges, corals, tunicates, and fungi to fully explore the potential for 
new chemistry and ultimately new drug candidates.  
1.3. Marine Natural Products Chemistry 
According to a review by Baker et al. in 2007, Antarctic corals have been the source of 
two third of the forty eight compounds isolated from cold water species of soft corals.7 Although 
the cold waters are devoid of reef building corals, the abundant soft-bodied corals have provided 
beneficial chemistry, mostly dominated by terpenoids.7 Octocorals have been the prominent source 
of chemically diverse compounds like sesquiterpenes, diterpenes, higher terpenes, alkaloids, and 
polyketides. Eleutherobin, isolated from an Australian Eleutherobia sp., is one of the most promising 
coral compounds as anti-tumor agent with modality of action mirroring that of taxol.  
 
Eleutherobin 
Despite the low total number of secondary metabolites reported from tunicates, a significant 
fraction of these compounds showed potent cytotoxicity.11,21 The Antarctic Synoicum adareanum 
has been the source of five new macrolide compounds called palmerolides. From this series, 
palmerolide A showed  antitumor activity against various mammalian cancer cell lines.22  The 
meridianins, isolated from the ascidian Aplidium meridianum, have been found to prevent cell 
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proliferation and induce cell apoptosis.7 Meridianins B  and E, also have activity against different 
kinases at micromolar concentrations.7  
 
Palmerolide A 
                             
      Meridianins B                                                                    Meridianins E    
 
Bioassay guided fractionation of Aplidium sp. resulted in two new monoterpenoids, rossinone A 
and B. Rossinone B has shown antiproliferative and antiviral effects against HSV-1, antifungal 
activity against Trichophyton mentagrophytes, and antibacterial towards Bacillus subtilis.22 
Feeding-deterrent activity against the Antarctic sea star O.validus was observed from the extract 
obtained from the tunicate A. fuegiense, leading to the isolation of new rossinones B family 
meroterpenoids.22 Other interesting compounds isolated from this genus of tunicates have come 
from A.glabrum, which prevent the onset of cancer in animal model.23 These compounds, named 
glabruquinone A and minor isomer glabruquinone B, are structurally similar to ubiquinone, and 
showed anticancer activity against HCT-116, MEL-28, and HT-460 on human tumor cells with 
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IC50 values of 12.7, 17.5, and 50.5 μM, respectively.7,23 Some of the richest sources of bioactive 
natural products are sponges, and fungi which are discussed in detail within the following sections. 
 
Rossinone A 
         
 Rossinone B 
                    
              Glabruquinone A                                                                   Glabruquinone B         
 
1.4. Drug Discovery from Marine Endophytes  
Studies of marine fungi represent one of the fastest expanding fields when compared to other 
unicellular organisms. The isolation of five new anserinones from deep-water (4380 m) 
Penicillium corylophilum began the search for new compounds from deep-water marine derived 
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fungal cultures. Out of these five, only (+)-formylanserinone B showed modest selectivity against 
MDA-MB- 435 breast cancer cell line.7 Penicillium sp., which came from a deep sea sediment 
(5080 m), yielded a diverse range of compounds; four meleagrin analogues and six new diterpenes, 
named conidiogenones B–G. Bioactivity screening of these groups of compounds revealed 
meleagrin B was moderately cytotoxic against MOLT-4, BEL-7047, HL60 and A549,  while 
conidiogenone C showed promising activity against BEL-7047 (0.9 μM) and  HL60 (0.038 μM).22  
                   
(+)-formylanserinone B       Meleagrin B 
 
Conidiogenone C  
Spiromastix sp., fungus from collected from south Atlantic Ocean at 2869 m, yielded 
Spiromastixones A–O.22  From this suite, spiromastixone J showed effective inhibition of 
vancomycin-resistant Enterococcus sp. (VRE). This particular fungus strain also produced eleven  
new spiromastols, of which several show significant antibacterial activity.11,22 Versicoloid A,  an 
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alkaloid  isolated from Aspergillus versicolor collected from the Indian Ocean showed significant 
activity and has  potential to be a lead antifungal for agricultural applications.22 
                                            
 Spiromastixone J       Versicoloid A  
One of the most unique compounds isolated as a natural product was epicoccamide, was isolated 
from a jellyfish-derived fungus Epicoccum purpurascens. Epicoccamide consists of unusual 
subunits of glycosidic, fatty acid, and tetramic acid, which are most likely derived from three 
distinct biosynthetic pathways. Unlike most tetramic acid derivatives, epicoccamide did not show 
bioactivity in a number of bioassays.7 Stereochem? 
 
Epicoccamide 
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1.5. Drug Discovery from Marine Sponges 
 To date, approximately 20,000 bioactive compounds have been isolated from marine sources.24 
Sponges are the most studied marine organisms with 50% of bioactive compounds isolated from 
this source.24 On average, sponges produce 200 compounds per year essentially making them one 
of the most studied organisms..22  In spite of the chemical abundance and its affiliated bioactivity 
in the porifera phylum the quest for novel bioactive compounds is hindered by the limited supply 
of these compounds, as they are often found in minute amounts in the sponge tissue. Low yields 
even from large amounts of extracted biomass has been a factor moving pharmaceutical companies 
away from natural products and towards synthetic approaches.  
Despite the continuous effort of these companies, the occasional epidemics of different viral 
infections, such as Ebola, and Zika the need for new antiviral drugs is inevitable. Similarly, 
Yasuhara-Bell and Lu et al, have cited that half of the recently discovered antiviral compounds are  
aimed at the management of the human immunodeficiency virus (HIV), for which sponges have 
represented a rich source of leads.24 Sponges have been a rich source for promising antiviral leads 
since the 1950’s.3  
In the early 1950s, pharmaceutical interest surrounding sponges began with the investigation of  
arabinose sugars (spongouridine and spongothymidine) isolated from a Caribbean sponge Tethya 
crypta (Tethylidae) by Bergmann et al.1,25 These compounds contain D-arabinose, as opposed to 
D-ribose nucleosides, and were reported to exhibit anticancer activity. Following their synthesis 
in 1960 by Baker lab, many derivatives were synthesized and screened, Ultimately leading to the 
development of ara-A (Vidarabine®, Vidarabine Thilo®) and ara-C (Cytarabine, Alexan®, 
Udicil®); which are derivatives of spongouridine and spongothymidine, respectively.26 Ara-A has 
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since been withdrawn from the market due to resistant viral strains.27 Ara-C, however, remains on 
the market for treatment of acute myeloid leukemia, acute lymphocytic leukemia, chronic 
myelogenous leukemia, and non-Hodgkin's lymphoma. In addition, derivatives of Ara-C are 
approved for the treatment of pancreatic, breast and bladder cancer.26 
                                                 
         Spongouridine                                                                               Spongothymidine 
 
In 1974 another effective antiviral lead came from a demosponge, Dysidea avara, which yielded 
avarol; a sesquiterpenoid hydroquinone with drimane skeleton, as well as a quinone analog.28,29 
The chemical structure was elucidated using chemical degradation, while its absolute 
configuration was determined later.29 This compound displays modest dose-dependent antiviral 
activity on the Human Acquired Immune Deficiency Syndrome (AIDS) and human T-
lymphotropic retrovirus (HTLV III)/lymphadenopathy-associated virus. In vitro studies have 
shown the bioactivity of Avarol in human H9 cells in vitro to be 0.1 µg/mL. In addition, this 
compound displays low toxicity in mice (LD10: 111 mg) while maintaining a high therapeutic 
index. Its ability to cross the blood brain barrier increased interest because HIV-1 infects brain 
cells in AIDS patients. Several studies indicated the importance of avarol as an antiviral agent 
because of its specificity in converting the viral genomic RNA into proviral DNA.30  While the 
biosynthetic pathway by which avarol is synthesized is not yet known, it is postulated that this 
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compound uses the shikimate pathway. Although the biosynthetic origins of this compound remain 
unknown, it was chemically synthesized by Ling et al. in 1999.31 Further in vitro biological activity 
evaluation showed AChE inhibition by avarol derivatives which showed its potential as 
neuroprotective agent for Alzheimer’s disease.31  
 
Avarol 
Continuing the success story of metabolites from sponges in drug discovery is the macrocyclic 
polyether, halichondrin B. Isolated from Halichondria okadai, halichondrin B was found to have 
strong cytotoxic activity against leukemia which prompting preclinical evaluations.32 The 
advancement of halichondrins as drugs has been largely impeded by difficulties synthesizing 
sufficient quantities for developmental studies.                                   
 
  
Halichondrin B 
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In 1998, however, halichondrin B received new lease of life when the Kishi lab at Harvard 
University discovered that the pharmacophore resides in the macrocyclic lactone moiety.33 
Researchers then synthesized the resulting drug, eribulin mesylate, for preclinical development 
later the same year. Eribulin mesylate’s activity was equal to that of natural product halichondrin 
B. The compound was classified as a tublin-binding anticancer agent with unique tublin activity 
and more potent activity than paclitaxel.34,35 In 2002, eribulin mesylate entered Phase I clinical 
trials, and was later approved by the FDA in 2010, under the trade name halaven for the treatment 
breast cancer.35,36  
 
Eribulin mesylate 
Found primarily in the Pacific and Indian Oceans, Mazamines represent another family of sponges 
containing compounds with wide range of biological activities. Manzamines are characterized by 
β-carbonile heterocycles and polycyclic diamine moieties containing an isoquinoline ring.37 These 
compounds have caught the attention of synthetic and biomedical chemists due to their potent 
biological activities against cancer, AIDS, tuberculosis, and inflammatory diseases, attracting the 
interest of synthetic and biomedical researchers.30 
  The first compound of this series, manzamine A hydrochloride or keramamine A, was isolated 
from an organic extract of a sponge belonging to the Haliclona genus.38,37 Higa et al. reported that 
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the compound showed significant anticancer activity (0.07 pg/mL on P388 mouse leukemia 
cells).38 A recent study regarding the pharmacokinetic properties performed in rats indicated that 
manzamine A displayed a long half-life, good oral bioavailability, and low metabolic clearance.30 
This study demonstrated the promising potential of manzamine A as a lead compound. 
Interestingly, around 100 manzamines have been reported, with different carbon frameworks and 
functionalities.37 
 
Keramamine A  
A new polyketide, PM060184, has been isolated from the sponge Lithoplocamia lithistoides; 
collected from shallow waters (6-20m) off the coast of Madagascar. The structure of PM060184, 
reported in 2013 by Mar Pharma of Spain, was elucidated through 1D and 2D nuclear magnetic 
resonance (NMR) experiments and the absolute configuration at  C-10 was determined by applying 
Marfey's method.  The paper also illustrated the total synthesis of PM060184. Interestingly, this 
compound was found to have antimitotic properties in human tumor cells. The mechanism-of-
action was found to be tublin-binding, similar to paclitaxel, the natural vinca alkaloids, and the 
above mentioned halichondrin B.39    
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PM060184 
It was observed that PM060184 suppresses the interphase and mitosis of cell division by inhibiting 
tubulin polymerization and microtubule shortening. On the basis of its distinct activity and its 
favorable safety profile, PM060184 entered clinical trials in 2013.39,40 It has since finished Phase-
I clinical trial and is under clinical evaluation with promising potential as a new anticancer agent. 
An extract from the Okinawan sponge Xestospongia sapra yielded a cardiotonic compound 
subsequently named xestoquinone. X. sapra, collected at a depth of 10 and 20 m, underwent 
bioassay guided fractionation after the methanolic extract showed cardiotonic activity in guinea 
pigs.  The structure of the active compound was elucidated by spectral data.41 Further assays found 
xestoquinone is not only a potent cardiotonic agent but also exhibits antiproliferative, antimalarial, 
and antifungal activity.41,42   
 
Xestoquinone 
Xestoquinone was later synthesized by Harada et al. in 1989 using a palladium (0)-catalyzed 
polyene cyclization of naphthyl triflate.43 More recently, Different cellular assays are being 
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conducted to fully understand the mechanism of Xestoquinone and its derivatives with the hopes 
of applications in  animal studies.44  
The cold-water sponge, Dendrilla membranosa, has also proved to be a rich source of bioactive 
compounds in the last few decades. The chemical investigation of this sponge started after studies 
by Dayton et al. revealed that D. membranosa was not being consumed predators of their natural 
benthic community. They postulated that the sponge was utilizing a chemical defense mechanism 
due to the lack of any unobservable physical defenses. Studies showed the defensive constituents 
of this sponge yielded a series of diterpenes. Darwinolide, a new diterpene, was isolated from the 
sponge in 2016. This compound displays 4-fold (33.2 μM) selectivity against the biofilm phase of 
methicillin-resistant Staphylococcus aureus (MRSA) compared to planktonic phase. 
 
 
Darwinolide  
 The biosynthetic pathways are believed to follow the gracilane pathway, similar to the other 
known aplysuphurides with rearrangements resulting in an expanded ring. This remarkable 
selectivity will provide a promising scaffold for leads in the quest for new antibacterial drugs.34 
Currently, numerous approaches are being applied for the total synthesis of darwinolide.  
1.6. Conclusion 
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 The resistance of microbes to different antimicrobial drugs remains a primary concern to public 
health today. Science is in a constant race against pathogenic microorganisms due to the rapid rate 
of resistance formation to new drugs (usually within a few years). With the discovery of 
vancomycin-resistant enterococci (VRE) and MRSA, the need for rapid and sustained 
development of new antibacterial agents is imperative.24,45,46 It has been observed from multiple 
screening studies that marine organisms elicit significant antibacterial activity including several  
novel antibacterial candidates, despite the lack of an antibacterial product on the market.24   
While combinatorial chemistry continues to play a major role in the modern drug development 
workflow, the compilation of natural product and natural product-like libraries continues. Marine 
organisms can give unpredictable results at times, as closely related chemicals can be produced 
from totally distinct environments, or a single species may produce varying metabolites depending 
on the site of collection. This diversity has been an attractive lead for research that has provided 
numerous compounds with a potential to develop into drugs. In addition to the few instances of 
marine-derived products on the market, a number of potentially promising compounds are 
discovered on a daily basis. The combination of attractive structures and biological activity 
displayed by the marine natural products will undoubtedly represent a huge therapeutic potential.  
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2. Chemical Investigation of Antarctic Marine Sponges 
2.1 Sponge metabolites and their pharmaceutical significance 
In terms of significant contributions in nature to the biomedical sciences, marine sponges have 
been an important source of potential drugs for various diseases like cancer, infectious diseases, 
viruses and inflammation.1 Secondary metabolites isolated from sponges are structurally diverse 
and have shown interaction with important biological receptors, many of which have implications 
for treating human disease.2,3,4 This prolific secondary metabolite production is thought to be the 
result of chemical defenses produced by the sedentary sponges. Among the compounds produced 
by sponges are cyclic peptides, sterols, terpenes, peroxides, fatty acids, etc.5  
Kirkpatrickia variolosa, a bright red sponge, is known to produce a group of compounds named 
variolins with their characteristic pyridopyrrolopyrimidine ring system. Variolins show potent 
activity toward the P388 cancer cell line.3,6,7 Variolin B displays the highest activity and, although 
various derivatives of variolin B have been synthesized and screened, none showed greater activity 
than the natural product itself.3  
2.2 Research Objective  
 Antarctic waters are rich in biodiversity with compounds isolated from cold-water sponges that 
are regarded as important drug candidates.8,9 Our group has been exploring the Antarctic benthos 
for years and compiled a collection of species from different years and locations within the 
Antarctic archipelago. Hence, this project focused NMR guided chemical investigation of two 
species of sponges collected in 2003 and 2016. Hence the aim of this project was to conduct NMR 
guided chemical investigation of species of sponges collected in 2003 and 2016 in order to 
determine their potential as lead compounds.  
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2.3 Isolation and Characterization of PSC03-33  
2.3.1 Collection, Extraction and Isolation of SGH-1 
Kirkpatrickia variolosa (Figure 2.1) was collected by SCUBA diving in 2003 from Palmer 
station, Antarctica. The specimen was kept frozen until it was lyophilized and subjected to 
extraction in MEOH-DCM (1:1) subsequently three times, followed by a second iteration of 
extractions using MEOH-Water (1:1). After concentrating the non-polar extract in vacuo, a 
liquid-liquid partition using 70% aqueous MEOH:Hexane helped to separate unwanted fatty 
acids from the extract. The resulting polar layer was prepared for MPLC by loading it onto C-
18 silica gel. 
 
Figure 2.1. Kirkpatrickia variolosa. Photograph supplied by Bill J. Baker, University of South 
Florida. 
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Scheme 2.1. Extraction scheme for Kirkpatrickia variolosa  
 
The sample loaded on C-18 silica gel was subjected to reverse phase MPLC with ELS and UV 
detectors (see appendix A for chromatogram) using a gradient of water and methanol. From the 
ten fractions collected, the less polar fraction J displayed interesting aromatic peaks in the NMR 
spectrum and was therefore selected for further separation using Sephadex LH-20®, activated with 
100% MeOH overnight. After NMR analysis of the resulting fractions, fraction seven was 
subjected to Sephadex LH-20® column chromatography with MEOH-DCM (1:1) to afford a pure 
compound, SGH-1. 
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2.3.2 Characterization of SGH-1 
 
SGH-1 
SGH-1 is a yellow powder with the molecular formula C14H11N7O, obtained from HRESIMS m/z 
294.10 [M+H]+. The 1H NMR spectrum of SGH-1 displayed aromatic signals at δH 8.16 (br d), δH 
6.82 (d), δH 7.24 (d), δH 7.64 (br d), δH 7.15(d) and δH 8.28 (br d) each of which integrated to one 
proton. The multiplicity indicates the protons are in pairs within each other. In addition, the broad 
signals δH 8.50 (s), δH 7.00 (s) and δH 9.79 (s) are indicative of the primary amine groups. The 13C 
NMR spectrum also indicated the presence of pyrrollopyridine and pyrimidine rings. Through 
comparison of NMR and mass spectral data, it was concluded that fraction SGH-1 was the known 
compound, variolin B. In the 1H NMR data of both published and experimental spectra, a 
difference in the chemical shift on protons of the amine group on C-10 was observed. This is due 
to the restricted rotation of N10’ created by the hydrogen bonding from N3’ and N7’. Interestingly, 
the chemical shift of the carbon C-10 and C-14 is also different due to the possibility of C-10 being 
shielded by the incomplete pyrrolopyrimido ring system. It is noteworthy to mention the hydroxy 
group on C-1 was likely not observed due to the highly de-shielded chemical shift that is promoted 
by its hydrogen bonding to N11’.  
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Table 2.1. 1D NMR data for SGH-1, and Variolin B7 in DMSO. 
Position δCb  δCb δH a (m, J(Hz))  δH a (m, J(Hz)) 
 Variolin B SGH-1 Variolin B SGH-1 
 
1 
 
 
159.9 
 
 
158.2 
 
 
--- 
 
--- 
2 107.6 107.45    6.90 (d, 5.5, 1H) 6.82 (d, 5.6, 1H) 
3 143.2 143.0 8.26 (dd, 5.6, 1H) 8.16 (br d, 5.6, 1H) 
4 145.0 144.5 --- --- 
5 111.2 111.1 --- --- 
6 99.6 99.4 --- --- 
7 137.1 136.9 --- --- 
8 160.1 159.9 8.37 (br d, 5.9, 1H) 8.28 (br d, 5.9, 1H) 
9 106.1 105.8  7.23 (d, 5.41H)  7.15 (d, 5.9, 1H) 
10 150.3 150.2 --- --- 
11 161.5 161.3 --- --- 
12 100.4 CH 100.2 7.31 (dd, 6.9, 1H) 7.24 (br d, 6.4, 1H) 
13 144.6 CH 144.8   7.73 (br d, 6.6, 1H) 7.64 (br d,6.3, 1H) 
14 158.4 C 159.7 --- --- 
 OH --- 16.1 --- 
 NH2 ---   8.6 (br m) 
  9.9 (br m) 
8.50 (br s, 1H) 
9.79 (br s, 1H) 
 NH2 ---   7.07 (br m) 7.00 (br m, 2H) 
                                                         
a 1H NMR spectrum recorded at 500 MHz; b 13C NMR spectrum recorded at 125 MHz. 
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2.4 Isolation and Characterization of PSC16-39  
2.4.1 Collection, Extraction and Isolation of SGH-2 
In 2016, an orange encrusting sponge (Figure 2) was collected by using SCUBA diving at Laggard 
island on the western peninsula of Antarctica. The freshly collected sponge was freeze dried 
immediately to prevent degradation.  
 
Figure 2.2. Image of unknown sponge species, PSC16-39. Photograph supplied by Bill J. Baker, 
University of South Florida. 
The marine sponge was exhaustively extracted with MEOH-DCM (1:1) at room temperature for 
three days. After air drying, the extract then was then partitioned with 70% MEOH: Hexane to 
remove the more non-polar components of the extract. The methanol fraction was loaded to silica 
gel for normal phase MPLC using hexanes and ethyl acetate as its eluents (see appendix A for 
chromatogram). The more polar fraction E was further subjected to reverse phase HPLC with 
H2O:MeOH (5:95 → 0:100) gradient system to yield three fractions. From these three fractions, 
fraction two was a pure compound labelled SGH-2 accordingly. 
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Scheme 2.2. Extraction scheme for PSC16-39. 
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2.4.2 Characterization of SGH-2  
 
 
                                                                                SGH-2 
In the 1H NMR of SGH-2, C10H14N2O5, chemical shifts at δH 7.85 (s), δH 2.27 (m), δH 2.32 (m), δH 
6.44 (dd), δH 4.47 (m), and δH 3.98 (m) along with the carbon resonances at δC 87.2 (CH, C-3), δC 
39.7 (CH2, C-3’), δC 70.6 (CH, C-4’), δC 83.9 (CH, C-5’), and δC 61.5 (CH2, C-8), supported the 
presence of a pentose moiety in the molecule. The other prominent signal was the methyl signal at 
δ12.7 that can be tentatively associated with methyl resonance. The carbonyl signals at δ162.6 and 
δ149.1 clearly indicated the presence of nitrogen. The above NMR evidence with HRESIMS m/z 
243.1025[M+H]+ established the isolated compound is thymidine despite the fact multiplicity and 
J-coupling data was not provided in the publication. 
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Table 2.2 1D NMR data for SGH-2 in DMSO, and  Thymidine10 in D2O 
 
a 1H NMR spectrum recorded at 500 MHz; b 13C NMR spectrum recorded at 125 MHz.  
 
 
 
 
 
Position δCb δCb δH a δH a (m, J(Hz)) 
 Thymidine SGH-2 Thymidine SGH-2 
2’ 87.8 87.2 6.28 6.44 (dd, 7.64, 6.24, 1H) 
3’ 39.8 39.7 2.40 
2.39  
2.27 (m, 1H) 
2.32 (m, 1H) 
4’ 70.8 70.6 4.04  3.98 (q, 3.79, 1H) 
 
5’ 86.3 83.9 4.49  4.47 (dt, 5.82, 2.99, 2.99, 1H) 
2 152.4 149.1 --- --- 
4 167.3 162.6 --- --- 
5 112.7 109.4 --- --- 
6 138.9 135.8 7.68  7.85 (s, 1H) 
7 12.8 12.7 1.89  2.02 (d, 0.98, 3H) 
8 62.5 61.5 3.79 
3.86  
3.77 (d, 3.94, 11.63, 1H) 
3.84 (d, 11.63, 11.63, 1H) 
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2.5  Summary and Conclusions 
The marine environment, particularly sponges, is a rich source of new compounds with 287 novel 
bioactive metabolites isolated in 2008 alone.11 Given this resource our lab seeks to find a vast 
potential of new lead compounds. Chemical investigation of an unidentified sponge led to the 
isolation of known secondary metabolite thymidine. Nucleosides were first isolated from the 
marine sponge Cryptothethya crypta by Bergmann and co-workers in the 1950’s.12 Additionally 
modified nucleosides have also been isolated from sponges and algae.12,13,14,15,16 Therefore, 
nucleosides and purine derivatives are known to be isolated from marine sponges. Moreover, from 
the collection of Kirkpatrickia variolosa, variolin B was isolated and its structure was elucidated 
using NMR and MS techniques. Variolin B is a rare marine alkaloid that displayed promising 
activity as an anticancer and antiviral soon after its isolation. Despite this promise the development 
of variolin B has been hindered by its low stability in water.17 However, with such promising 
compound from this sponge, extracts that feature specific and potent bioactivates can further be 
investigated for chances of discovering new compounds.  
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3. Dereplication and Chemical Investigation of a Floridian Mangrove Fungal Endophyte 
3.1. Significance of fungal dereplication strategies  
Since the discovery of penicillin in 1928, an increasing number fungal metabolite are isolated and 
evaluated every year for their biological significance.1 Natural products with applications ranging 
from antibiotics to industrial chemicals have been isolated from fungi.2 As of 2016, around 50,000 
marine natural products were reported3 and approximately 4,000 new compounds from natural 
sources are added per year to the already impressive number of known natural products.4 This 
significant rate has been possible due to advancements in fungal isolation and culturing 
methodology. 
With this increasing number of fungal compounds reported in the literature, isolation of nuisance 
compounds, particularly mycotoxins, remain a major obstacle in modern fungal natural product 
drug discovery.4,5,6 To rectify this, researchers began compiling public databases of natural 
products and their corresponding spectral data to remove this bottleneck in the discovery process. 
This technique is termed dereplication and has revolutionized the natural product discovery 
workflow. This is typically achieved using mass spectrometry or tandem mass spectrometry 
databases.4 The ability of tandem MS databases, such as METLIN-AMRT-PCDL and Mycotoxins-
AMRT-PCDL, for dereplication has essentially become a critical stage in natural products drug 
discovery. Tandem MS is beneficial as it produced fragmentation patterns unique to each 
compound.7 This assist with the identification of known compounds in an extract which reduce 
the time and resources used previously. With the identification of these known compounds 
unidentified peaks can be further evaluated for new compounds.  
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3.2. Research objective 
With many new compounds isolated from fungi every year, dereplication methods have become 
imperative in fungal natural products research, to identify toxic and known compounds early in 
investigations.  In addition to the chemical investigation of a fungus for bioactive metabolites, 
herein is presented methodology utilizing two databases, METLIN-AMRT-PCDL and 
Mycotoxins-AMRT-PCDL, to identify toxins and other known compounds from the MPLC 
fractions of crude fungal extracts. 
3.3 Isolation and Characterization of HM13-23B-20C 
3.3.1 Collection and Culturing of Fungi 
A collection trip of Baker’s lab in 2013 aimed at harvesting tissue of mangrove tree from 
Honeymoon Islands in Florida. The collected samples were taken in lab and endophytes were 
isolated using the following plating protocols. The mangroves were put on petri dishes with 
different nutrient media components (SDB, PDB, TSA, Actinomycete Isolation Agar, Malt Extract 
Agar) and agar. These plates were incubated for 4 weeks under room temperature. Once the plate 
was covered with growth of different colonies, each colony was isolated and regrown on SDA. 
After a pure colony was established, it was subsampled for screening. The fungus used in this 
project, HM13-23B-20C, demonstrated activity against Naegleria fowleri.  
3.3.2 Scale-up  
The scale up protocol was established to mimic the screening culture protocol. According to this 
optimized procedure, HM13-23B-20C was grown again on SDA plates from the glycerol stock. 
After the colony was established, fungal plugs (1 mm x 1 mm) were placed in Falcon™ tubes 
containing 50mL of SDB. The fungal mixture was then poured in to a prepared rice media.. The 
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rice was prepared by using 300g and 500mL DI water in 3T Unicorn bags. Rice was sterilized by 
autoclaving on a liquid cycle for 30 minutes at 121oC. After 21 days of growth in rice, the material 
was transferred to a large beaker and extracted overnight by MEOH:EtOAc (1:1), followed by two 
days of 100% EtOAc. The extracts were filtered and concentrated for isolation of compounds. 
3.3.3 Isolation of SGH-3 AND SGH-4 
Before undergoing isolation, a portion of the extract was sent for bioassay. Unfortunately, the 
extracts lost their activity against N. fowleri. Despite this, the 1H NMR spectrum revealed 
potentially interesting chemistry. The crude extract was further purified following NMR guided 
isolation (Scheme 3.1.). The crude extract was partitioned between EtOAC and water to remove 
salts and media components. This was followed by normal phase MPLC of the EtOAc portion 
which rendered six fractions (see appendix B for chromatogram). 
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Scheme 3.1. Extraction scheme for HM13-23B-20C  
 NMR analysis led to the prioritization of fractions E and F for further investigation.  Normal phase 
HPLC of fraction E on silica column with n-hexanes: ethyl acetate gradient yielded 10 fractions. 
Fraction three was the most interesting fraction and was further purified on silica to yield a pure 
compound, SGH-3. Similarly, fraction F was further subjected to normal phase HPLC with n-
hexanes: ethyl acetate to give pure compound, SGH-4. 
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3.3.4 Characterization of SGH-3 
 
SGH-3 
SGH-3 was isolated as a light-yellow oil with a molecular formula of C16H22O3 suggested by its 
HRESIMS m/z 263.1569 [M+H]+. The 1H NMR spectrum indicated a polyketide derivative. 
Moreover, 13 C NMR showed the presence of three methyls, six methines and four quaternary 
carbons. The three olefinic protons at δH 5.73, δH 6.22, δH 5.46 were associated with the four 
carbons at δC 135.5 (C-9), δC 132.2 (C-11), δC 128.2 (C-12) along with the quaternary δC 129.2 
(C-10). One ketonic carbonyl at δC 212.7 was present at the 13C spectrum of SGH-3.  The positions 
of the quaternary carbons were confirmed by HMBC experiments. The presence of the decalin 
skeleton was indicated by HMBC correlation of C-14 to C-13, C-4, and C-12. Based on 1  NMR 
and HRESIMS data, the chemical structure was determined to be  identical to versiol.  Versiol was 
previously isolated from Aspergillus versicolor, Spororamia affinis, and Penicillum 
striatisporum.8 Configuration of stereocenters were not confirmed due to lack enough mass to 
render NOESY through space correlations, and crystallization of the sample has yet to be 
accomplished.  
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Table 3.1. 1D NMR data for SGH-3, and Versiol9 in CDCL3. 
                   
    a 1H NMR spectrum recorded at 400 MHz; b 13C NMR spectrum recorded at 200 MHz. 
Position δC
b δC
b δH 
a (m, J(Hz)) δH 
a (m, J(Hz)) 
 Versiol SGH-3 Versiol SGH-3 
1 60.0 60.1 3.97 (ddd, 12.1, 11.8, 3.4, 1H) 
4.11 (dd, 11.8, 8.9, 1H) 
3.97 (m, 1H) 
4.11 (dd, 11.8, 8.9, 1H) 
 
2 38.6 38.7 2.36 (dd, 15.1, 3.4, 1H) 
2.87 (ddd, 15.1, 12.1, 8.9, 1H) 
2.36 (dd, 15.2, 3.3, 1H) 
2.87 (ddd, 15.2, 12.2, 8.8, 1H) 
 
3 212.8 212.7           ---             --- 
4 57.0 57.1           ---             --- 
5 41.7 41.8 3.32 (q, 3.0, 1H)  3.33 (m, 2.7, 1H) 
6 67.0 67.2 3.96 (m, 1H)  3.96 (m, 1H) 
7 39.2 39.4 1.30 (m, 1H)  
1.95 (dt, 4.6, 13.3, 1H)  
1.29 (m, 1H)  
1.97 (dt, 4.5, 13.2, 1H) 
 
8 25.3 25.5 2.63 (m, 1H)  2.64 (m, 1H) 
9 135.5 135.7 5.72 (br s, 1H)  5.73 (br s, 1H) 
10 129.9 129.2         ---          --- 
11 132.2 132.3 6.21 (d, 9.5, 1H)  6.22 (d, 9.6, 1H) 
12 128.2 128.4 5.44 (d, 9.5, 1H)  5.46 (d, 9.5, 1H) 
13 78.6 77.4         ---          --- 
14 20.8 20.9 1.27 (s, 3H)  1.28 (s, 3H) 
15 13.1 13.3 1.10 (s, 3H)  1.12 (s, 3H) 
16 21.0 21.2 1.04 (d, 7.1, 3H)  1.04 (d, 7.14, 3H) 
 
6-OH   1.77        --- 
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3.3.5. Characterization of SGH-4 
 
 
SGH-4 
SGH-4 molecular formula, C32H30O14, was determined by HRESIMS at m/z 639.1632 [M+H]
+, 
and was obtained as a pale-yellow gum.. The NMR spectra showed fifteen protons and sixteen 
carbons, indicated SGH-4 was a symmetrical dimer. 13C NMR spectrum indicated the presence of 
a conjugated ketone carbonyl δC 186.9 (C-9), one ester carbonyl δC 170.0 (C-12), three methines 
(δC 139.9 (C-3) and δC 107.3 (C-4) and δC 28.9 (C-6)), one methylene δC 36.0 (C-7), a methoxy δC 
53.0 (C-13), a methyl group δC 17.7 (C-11) and a oxymethine δC 75.3 (C-5). In addition, carbon 
resonances at δC 159.1 (C-1), δC 117.3 (C-2), δC 158.0 (C-4a), δC 101.3 (C-8a), δC 177.3 (C-8), δC 
106.6 (C-9a), δC 186.9 (C-9), δC 84.5 (C-10a), and δC 170.0 (C-12) supported the presence of nine 
quaternary carbons.  The two most deshielded 1H signals at δH 11.70, and δH 13.72 indicated the 
chelation of hydroxyl groups with carbonyl groups. Compared to previously reported data, SGH-
4 was confirmed to be secalonic acid D which was first isolated in 1970 from Penicillium 
 
 
 
 
 
44 
 
oxalicum.10,11 The stereochemical assignments of C-5 and C-6 were determined using 2D NOESY 
correlations  (see appendix B for spectrum).  
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Table 3.2. 1D NMR data for SGH-4 in CDCl3 , and secalonic acid D in DMSO
12
 
a 1H NMR spectrum recorded at 400 MHz; b 13C NMR spectrum recorded at 125 MHz. 
 
 
Position δCb δCb δH a (m, J(Hz)) δH a (m, J(Hz)) 
 secalonic 
acid D 
SGH-4 secalonic acid D SGH-4 
1 158.9 159.1 --- --- 
2 117.3 117.9 --- --- 
3 140.2 139.9 7.45 (d, 8.42, 2H) 7.47(d, 8.44, 2H) 
4a 158.5 158.0 --- --- 
4 107.5 107.3 6.63 (d, 8.42, 2H) 6.64 (d, 8.44, 2H) 
5 75.2 75.3 3.81 (d, 9.51, 2H) 3.94 (d, 9.72, 2H) 
6 29.9 28.9 2.31 (m, 2H) 2.43 (m, 2H) 
7 35.8 36.0 2.65 (dd, 8.42, 19.80, 2H) 
2.49 (dd, 6.22, 19.80, 2H) 
2.75 (dd, 8.44, 19.80, 2H) 
2.48 (m, 2H) 
8a 101.7 101.3 --- --- 
8 178.2 177.3 --- --- 
9a 106.3 106.6 --- --- 
9 186.6 186.9 --- --- 
10a 85.2 84.5 --- --- 
11 17.8 17.7 1.03 (d, 6.22, 6H) 1.19 (d, 6.22, 6H) 
12 170.0 170.0 --- --- 
13 52.6 53.0 3.61 (s, 6H) 3.74 (s, 6H) 
  2OH 13.72 (brs, 2H) 13.79 (brs, 2H) 
  2OH 11.70 (s, 2H) 11.76 (s, 2H) 
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3.4. Dereplication analysis of MPLC fractions 
After the isolation of these two well-known fungal metabolites, all MPLC fractions were subjected 
to automatic LC-MS/MS experiments for dereplication. Once spectral profiles were generated for 
each MPLC fraction; chromatograms were evaluated with Agilent MassHunter Qualitative 
Analysis. Metabolites from each fraction were identified using automated compound identification 
protocols, and were verified with LC-MS chromatogram. Once the metabolites are identified 
METLIN-AMRT-PCDL and Mycotoxins-AMRT-PCDL were used to identify any known toxic 
compounds. Secalonic acid D, a previously isolated mycotoxin from fraction F, was correctly 
identified as a major compound. Other metabolites such as koparin, phenylbutazone, 
sulfadimidine, emodin, baicalein, cetrimonium, 3-Dehydrosphinganine, 4-Methyldaphnetin, 
fisetin, and fenspiride were also generated as major components of the MPLC fractions. However, 
fenspiride, sulfadimidine, and phenylbutazone are not natural products. This is one of the 
drawbacks of these databases, specifically METLIN-AMRT-PCDL. Therefore, it is advisable to 
confirm whether the identified compounds are natural products or not. Besides, the major 
components of fraction A, B, C, and G were not identified by either database. Due to time 
constraints these fractions have not been purified yet but, they are prioritized for future purification 
and chemical analysis.   
                   
          Koparin                                       Phenylbutazone                          Sulfadimidine 
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            Emodin                                               4-Methyldaphnetin                            Fisetin 
 
 
 
                   
 
 
                        Cetrimonium                                                          3-Dehydrosphinganine 
 
 
 
Fenspiride 
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3.5. Summary and Conclusions 
Fungal endophytic libraries have long been used in drug discovery projects as a tool for new 
metabolite isolations. High throughput screening of the Floridian mangrove forest endophyte 
communities conducted by our lab showed promising activities against numerous targets.13 The 
two compounds discussed herein, were isolated from the control growth condition from one of 
these screened microorganisms. However, after tedious chemical investigations the isolated 
compounds were well known fungal metabolites; versiol and secalonic acid D. Re-isolation of 
known metabolites such as this, is a significant obstacle in the discovery of new fungal natural 
products. In order to overcome this standardized tandem MS experiments were used to 
successfully identify mycotoxins from the MPLC fractions. Thus, this project has verified that 
Tandem MS data can be used for dereplication purposes and the need to conduct such analyses to 
prioritize fractions containing potentially new chemistry. This analysis validated that known 
compounds can be identified from crude fractions by comparison to spectral databases such as 
METLIN and mycotoxin. It also illustrates the importance of the process, as multiple fractions 
with unknown chemistry were not prioritized for chemical investigation. Due to time constraints, 
the purification of these unknown compounds could not be completed. However, the dereplication 
process that was carried out after the isolation of two known compounds, helps to prioritize certain 
fractions for future isolation of new metabolites. 
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4. General Experimental Procedure 
MPLCs were performed on Teledyne Isco CombiFlash Rf 200i equipped with two types of 
detectors; evaporative light scattering (LT-II) and photodiode array (M20A). HPLC were 
performed on Shimadzu LC-20A equipped with ELSD and UV detectors. Normal phase HPLC 
used either Phenomenex Silica Luna [semi-preparative (100 Å, 250 x 10 mm, 10 μm) and 
analytical (250 x 4.6 mm, 5 μm)] columns. Reversed phase chromatography utilized Phenomenex 
C18 Luna [semi-preparative (250 x 10 mm, 5 μm) and analytical (100 Å, 250 x 4.6 mm, 5 μm,)] 
columns. HRESIMS was obtained on Agilent 6210 LC/MS equipped with Time of Flight (TOF) 
detector using Phenomenex Kinetex C18 column (50 x 2.1 mm, 2.6 μm) column. LC-MS/MS were 
performed on Agilent 6540 LC/QToF-MS with Jet stream ESI detection using Phenomenex 
Kinetex C18 column (50 x 2.1 mm, 2.6 μm) column. Varian 400, 500 or 600 MHz were used to 
record 1H NMR spectra. 13C data were recorded at 200 or 125 MHz. Residual deuterated solvents 
were purchased from Sigma-Aldrich and used as internal standards. NMR data was obtained in 
MEOD, CDCl3, and d-DMSO.  
 
5. Bioassay of Pure Compounds 
Once characterized all pure compounds are often screened against a range of human pathogens. In 
this regard, the pure compounds isolated in the two projects were screened against Clostridium 
difficile, ESKAPE and rA2 Rluc. rA2 Rluc is respiratory syncytial virus that expresses Renilla 
Luciferase which is  a leading cause of severe respiratory disease and hospitalizations in young 
children and immunocompromised adults.1 Variolin B, one of the isolated compounds, and its 
derivative deoxyvariolin B are known for their promising antiviral and anticancer activity since its 
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isolation.2,3,4 However, due to their inability to solubilize easily and lack of conclusive data on the 
DNA intercalator mechanism-of-action variolin B was set aside.3,5,6 Nevertheless, for this thesis it 
was tested against pathogens which are not reported in literature. Secalonic acid D is a known 
mycotoxin with cytotoxicity against human breast adenocarcinoma (MCF7) cell lines.7 
Interestingly, it also displayed a promising activity against biofilm formation of S. aureus at 6.25 
μg/ml without inhibition of cell growth. The remaining pure compounds isolated; 3-methyl-2'-
deoxyuridine and versiol didn’t have any significant activity reported. As a continuation of this 
project, antimicrobial and antiviral in vitro activities were tested on pure compounds, SGH 1-4. 
The samples were prepared with a concentration of 5 mg/mL in 150 μL DMSO and plated in 
Corning™ polypropylene microplates.  Multiple plates were prepared and distributed among our 
collaborators; Dr. Xingmin Sun in the college of medicine molecular medicine for C.difficile,  Dr. 
Lindsey Shaw in the department Cell Biology, Microbiology and Molecular Biology (CMMB) for 
testing against the ESKAPE pathogens and Dr.Michael N. Teng in the College of Medicine for 
rA2 Rluc assay.  Unfortunately, these compounds did not show any considerable antimicrobial or 
antiviral activity. Variolin B and thymidine showed relatively better activity in the C.difficile assay 
with an MIC 64 μg/mL.  MPLC fractions from the fungi extracts are presently being tested against 
C.difficile. Additionally, the pure compounds will continue to be screened in new biological assays 
not reported in their respective papers to exploit their therapeutic potential.  
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Appendix A: Experimental and supporting data for chapter 2 
 
MPLC Chromatograms 
NMR Spectra for SGH-1 
NMR Spectra for SGH-2 
 
 
 
RP MPLC Chromatogram for Kirkpatrickia variolosa, PSC03-33 
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1H NMR Spectrum (500 MHz, DMSO-d6) of SGH-1 
 
 
 
13C NMR Spectrum (125 MHz, DMSO-d6) of SGH-1  
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RP MPLC Chromatogram for PSC16-39 
1H NMR Spectrum (500 MHz, DMSO-d6) of SGH-2 
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13C NMR Spectrum (125 MHz, DMSO-d6) of SGH-2  
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1H-13C gHMBC-AD NMR Spectrum (600 MHz, DMSO-d6 ) of SGH-2 
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Appendix B: Experimental and supporting data for chapter 3 
 
MPLC Chromatograms 
NMR Spectra for SGH-3 
NMR Spectra for SGH-4 
 
 
 
NP MPLC Chromatogram for HM13-23B-20C 
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1H NMR Spectrum (500 MHz, CDCl3) of SGH-3 
 
 
 
13C NMR Spectrum (200 MHz, CDCl3) of SGH-3 
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1H-13C gHMBC NMR Spectrum (500 MHz, CDCl3) of SGH-3 
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1H NMR Spectrum (400 MHz, CDCl3) of SGH- 4 
 
 
 
13C NMR Spectrum (200 MHz, CDCl3) of SGH-4 
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1H-1H NOESY NMR Spectrum (500 MHz, CDCl3) of SGH-4 
 
 
 
